Antonio Rodríguez-Valiente

Antonio Rodríguez-Valiente

Auto-generated profile, based on publicly available information

Antonio Rodríguez-Valiente

Ear Research Group, Department of Otorhinolaryngology, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid , Madrid , Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2014 in International Journal of Audiology
Verified
Journal Article
Closed access
AVA. Rodríguez Valiente
A. Rodríguez Valiente
ATA. Trinidad
A. Trinidad
JBJosé Ramón García Berrocal
José Ramón García Berrocal
CGC. Górriz
C. Górriz
RCR. Ramírez Camacho
R. Ramírez Camacho
The aim of the present study was to study patterns in the extended spectrum of the human hearing (0.125 to 20 kHz) in order to obtain reference thresholds. Then, we compare our values with existing results at extended high-frequencies (8 to 20 kHz) in an attempt to establish new standards for potential international adoption. A prospective study in a group of otologically healthy subjects. A total of 645 subjects aged between 5 and 90 years were recruited. Pure-tone thresholds were determined for conventional and extended high-frequencies. There was an increase in the hearing thresholds as a function of frequency and age. For the 20 to 69 years old group, thresholds were lower in females than in males, especially at 12.5 and 16 kHz. Our threshold values are comparable to those presented in previous studies that used different instrumentation and populations. When comparing different studies the hearing thresholds were found to be similar. Therefore, it would be possible to establish international standard thresholds.

27 June 2006 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
JBJosé Ramón García Berrocal
José Ramón García Berrocal
AIAndrés Ibáñez
Andrés Ibáñez
ARAntonio Rodríguez
Antonio Rodríguez
Jose Angel Gonzalez-GarciaJose Angel Gonzalez-Garcia
Jose Angel Gonzalez-Garcia
JVJosé María Verdaguer
José María Verdaguer
RRRafael Ramírez-Camacho
Rafael Ramírez-Camacho

1 January 2016 in Acta Otorrinolaringológica Española
Verified
Journal Article
Closed access
AVAntonio Rodríguez Valiente
Antonio Rodríguez Valiente
AFAmaya Roldán Fidalgo
Amaya Roldán Fidalgo
IVIthzel M. Villarreal
Ithzel M. Villarreal
JBJosé Ramón García Berrocal
José Ramón García Berrocal

1 January 2006 in Medical Hypotheses
Verified
Journal Article
Closed access
RRR. Ramírez-Camacho
R. Ramírez-Camacho
JBJosé Ramón García Berrocal
José Ramón García Berrocal
ATA. Trinidad
A. Trinidad
Jose Angel Gonzalez-GarciaJose Angel Gonzalez-Garcia
Jose Angel Gonzalez-Garcia
JVJ.M. Verdaguer
J.M. Verdaguer
RSRicardo Sanz-Fernández
Ricardo Sanz-Fernández

1 April 2016 in Experimental and Toxicologic Pathology
Verified
Journal Article
Open access
ARA. Roldán-Fidalgo
A. Roldán-Fidalgo
SSSergio Martin Saldaña
Sergio Martin Saldaña
ATA. Trinidad
A. Trinidad
Begoña Olmedilla-AlonsoBegoña Olmedilla-Alonso
Begoña Olmedilla-Alonso
ARA. Rodríguez-Valiente
A. Rodríguez-Valiente
RRR. Ramírez-Camacho
R. Ramírez-Camacho
Cisplatin is a commonly prescribed drug that produces ototoxicity as a side effect. Lutein is a carotenoid with antioxidant and anti-inflammatory properties previously tested for eye, heart and skin diseases but not evaluated to date in ear diseases. To evaluate the protective effects of lutein on HEI-OC1 auditory cell line and in a Wistar rat model of cisplatin ototoxicity. In vitro study: Culture HEI-OC1 cells were exposed to lutein (2.5-100 μM) and to 25 μM cisplatin for 24h. In vivo study: Twenty eight female Wistar rats were randomized into three groups. Group A (n=8) received intratympanic lutein (0.03 mL) (1mg/mL) in the right ear and saline solution in the left one to determine the toxicity of lutein. Group B (n=8) received also intraperitoneal cisplatin (10mg/kg) to test the efficacy of lutein against cisplatin ototoxicity. Group C (n=12) received intratympanic lutein (0.03 mL) (1mg/mL) to quantify lutein in cochlear fluids (30 min, 1h and 5 days after treatment). Hearing function was evaluated by means of Auditory Steady-State Responses before the procedure and 5 days after (groups A and B). Morphological changes were studied by confocal laser scanning microscopy. In vitro study: Lutein significantly reduced the cisplatin-induced cytotoxicity in the HEI-OC1 cells when they were pre-treated with lutein concentrations of 60 and 80 μM. In vivo study: Intratympanic lutein (1mg/mL) application showed no ototoxic effects. However it did not achieve protective effect against cisplatin-induced ototoxicity in Wistar rats. Although lutein has shown beneficial effects in other pathologies, the present study only obtained protection against cisplatin ototoxicity in culture cells, but not in the in vivo model. The large molecule size, the low dose administered, and restriction to diffusion in the inner ear could account for this negative result.

8 July 2006 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
Jose Angel Gonzalez-GarciaJose Angel Gonzalez-Garcia
Jose Angel Gonzalez-Garcia
AIAndrés Ibáñez
Andrés Ibáñez
RRRafael Ramírez-Camacho
Rafael Ramírez-Camacho
ARAntonio Rodríguez
Antonio Rodríguez
JBJosé Ramón García Berrocal
José Ramón García Berrocal
ATAlmudena Trinidad
Almudena Trinidad